For a 28-year-old unmarried male with moderate-to-severe plaque psoriasis, is secukinumab or ustekinumab the preferred biologic therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Secukinumab is the preferred choice for this 28-year-old male with moderate-to-severe plaque psoriasis

For a young adult with moderate-to-severe plaque psoriasis, secukinumab demonstrates superior efficacy compared to ustekinumab, with faster onset of action and higher rates of complete skin clearance, while maintaining a comparable safety profile. Both agents receive Grade A recommendations from the 2019 AAD-NPF guidelines 1, but head-to-head trial data consistently favor secukinumab.

Efficacy Comparison: Secukinumab Outperforms Ustekinumab

The most compelling evidence comes from direct comparison trials:

  • CLEAR study (52-week data): Secukinumab achieved PASI 90 in 76% of patients versus 61% with ustekinumab (P < 0.0001), and PASI 100 in 46% versus 36% (P = 0.0103) 2. At week 16, the difference was even more pronounced: 79% versus 57.6% for PASI 90 1.

  • CLARITY study: Secukinumab demonstrated superiority at week 12 with PASI 90 rates of 66.5% versus 47.9% for ustekinumab (P < 0.0001), and this advantage was evident as early as week 4 (16.7% vs 4.0%) 3.

  • Speed of response: Secukinumab shows significantly faster onset, with median time to PASI 50 of 2.8 weeks versus 6.3 weeks for ustekinumab 4. This rapid response is clinically meaningful for patient quality of life.

Quality of Life Benefits

Secukinumab provides superior patient-reported outcomes, which is particularly relevant for a young, unmarried patient where social and psychological impacts are significant:

  • At week 52,72% of secukinumab patients reported no impact of skin disease on their lives (DLQI 0/1) versus 59% with ustekinumab (P = 0.0008) 2
  • Greater reductions in psoriasis-related pain, itching, and scaling across all quality-of-life measures 2
  • Higher rates of complete skin clearance (PASI 100) matter for young adults in social and intimate relationships

Dosing Considerations

Secukinumab: 300 mg subcutaneous at weeks 0,1,2,3, and 4, then every 4 weeks 1

  • More frequent initial loading but monthly maintenance
  • The 300 mg dose is significantly more effective than 150 mg 1

Ustekinumab: For patients ≤100 kg, 45 mg at weeks 0 and 4, then every 12 weeks 1

  • Less frequent dosing (every 3 months) may appeal to some patients
  • However, efficacy is lower despite convenience

Safety Profile: Comparable Between Agents

Both medications demonstrate favorable safety profiles with no significant differences in serious adverse events 1:

  • Secukinumab: <0.4% develop neutralizing antibodies, not associated with loss of efficacy 1
  • Ustekinumab: <1% develop anti-drug antibodies 1
  • Both require tuberculosis screening before initiation
  • Neither has concerning signals for serious infections or malignancies in this age group

Important caveat: Both agents are considered safe for men attempting conception with their partners 1, which is relevant for this unmarried 28-year-old patient.

Clinical Decision Algorithm

For this patient, prioritize secukinumab if:

  • Rapid clearance is desired (social/professional reasons)
  • Maximum efficacy is the goal
  • Monthly injections are acceptable

Consider ustekinumab if:

  • Patient strongly prefers less frequent dosing (every 12 weeks)
  • Cost considerations favor ustekinumab (biosimilars now available) 5
  • Patient has concomitant psoriatic arthritis requiring joint protection (though both are effective, TNF inhibitors remain preferred for PsA) 1

Special Considerations for This Patient Population

The "unmarried" status is clinically relevant because:

  • Complete skin clearance (PASI 100) has greater psychosocial impact in young adults forming relationships
  • Secukinumab's superior PASI 100 rates (46% vs 36% at week 52) 2 provide meaningful benefit
  • Faster response reduces the psychological burden of visible disease

Real-world evidence supports guideline recommendations: A 2022 Korean study showed guselkumab superior for long-term response, but among the two agents in question, secukinumab demonstrated more rapid response while ustekinumab showed lower overall efficacy 6. A 2026 Chinese assessment ranked ixekizumab first, secukinumab second, and ustekinumab third for psoriasis treatment 7.

Common Pitfalls to Avoid

  1. Don't underdose secukinumab: The 300 mg dose is significantly more effective than 150 mg 1—always use the higher dose for moderate-to-severe disease
  2. Don't assume dosing convenience equals better outcomes: Ustekinumab's every-12-week dosing is appealing but comes at the cost of lower efficacy
  3. Don't forget to screen for psoriatic arthritis: If present, treatment selection may shift toward agents with joint protection data, though both drugs are FDA-approved for PsA 1

References

Related Questions

Is ustekinumab more effective than secukinumab for treating plaque psoriasis?
What is the recommended dosing regimen of Taltz (ixekizumab) for plaque psoriasis in adults and pediatric patients?
Can an adult with moderate-to-severe plaque psoriasis refractory to topical therapy use Taltz (ixekizumab), and what is the dosing schedule and required pre‑treatment screening?
What are the mechanism of action, dosing schedule, administration method, efficacy, safety profile, contraindications, and monitoring recommendations for ustekinumab?
What are the contraindications for using Tumor Necrosis Factor-alpha (TNFa) inhibitors, such as etanercept (Enbrel), adalimumab (Humira), or infliximab (Remicade), and Interleukin-23 (IL23) inhibitors, such as ustekinumab (Stelara), guselkumab (Tremfya), or risankizumab (Skyrizi), in patients with psoriasis?
How do losartan and spironolactone affect serum potassium levels?
Does mirtazapine cause withdrawal symptoms?
What are the risk factors for dacryocystitis?
What is the next step in management for a patient with long‑standing gastroesophageal reflux disease, chronic cough and mucus sensation, normal esophagogastroduodenoscopy and esophageal manometry, and who has already tried proton‑pump inhibitor therapy?
What empiric broad‑spectrum intravenous antibiotics should be given for neutropenic enterocolitis in a febrile patient with an absolute neutrophil count less than 500 cells/µL?
In a 63-year-old man with multiple lung nodules and a 4 cm left‑lung mass, which of the following primary cancers most rarely metastasizes to the lung: breast, kidney, melanoma, colon, or cervical cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.